Doximity, Inc. (DOCS) AI Stock Analysis

Doximity, Inc. operates a cloud-based platform tailored for medical professionals across the United States. Its platform equips members with specialized tools to facilitate collaboration among colleagues, coordinate patient care, conduct virtual visits, and manage their careers. It also delivers up-to-date medical news and research to keep practitioners informed. Catering primarily to pharmaceutical manufacturers and healthcare systems, Doximity enhances communication and efficiency across healthcare delivery. Founded in 2010 and headquartered in San Francisco, California, the company employs 880 people and provides digital healthcare solutions to connect the medical community nationwide.

Doximity grew annual revenue from $343.5M in FY2022 to $644.9M in FY2026, achieving a five-year revenue compound annual growth rate of 25.5%. Annual revenue increased 13.1% in FY2026, down from 20.0% growth in FY2025. Gross margin remained high at 89.1% in FY2026, while operating margin was 33.3%. Net income reached $196.1M in FY2026 with diluted earnings per share of $1.44. Over the trailing twelve months, revenue totaled $655.6M with a profit margin of 25.5%. In the latest quarter ended June 30, 2026, quarterly revenue grew 7.3% year-over-year, while quarterly earnings declined 51.9%.

As of June 30, 2026, Doximity held $687.8M in cash and short-term investments against $9.7M in total debt, resulting in net cash of $678.1M. The company reported a current ratio of 6.08 and a debt-to-equity ratio of 0.01 on shareholders' equity of $916.1M. In FY2026, operating cash flow reached $326.5M and free cash flow was $317.5M. Capital expenditures totaled $9.0M, and the company allocated $431.7M to share buybacks, reducing its share count by 11.7% over five years.

At a last close of $30.97, Doximity carried a market capitalization of $5.52B and an enterprise value of $4.06B. The stock trades at a trailing price-to-earnings ratio of 36.4x and a forward ratio of 19.8x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its enterprise value-to-EBITDA multiple stands at 19.3x versus the peer median of 12.0x, while its price-to-sales ratio is 8.4x versus 4.1x. Over the past year, Doximity shares declined 54.0%, trailing the S&P 500 return of 16.8%.

Wall Street analysts coverage includes 3 Strong Buy, 5 Buy, 11 Hold, 1 Sell, and 1 Strong Sell ratings. The mean price target of $30.44 implies a 1.7% decline from the last close of $30.97. For the fiscal year ending March 31, 2027, consensus estimates project revenue of $677.6M and earnings per share of $1.35, representing an estimated earnings decline of 10.9%. Doximity beat earnings estimates in 2 of the last 4 quarters, and its next earnings report is scheduled for November 5, 2026.

This page is an AI-written research summary of Doximity, Inc. (DOCS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DOCS income statement, DOCS balance sheet, DOCS key metrics, DOCS analyst forecast, DOCS chart. See the DOCS stock overview for the latest quote and news.